COLLPLANT HOLDI / S (NASDAQ: CLGN) is one of 27 companies that have been traded publicly in the "Surgical equipment and supplies" industry, but how it is counterparted to competitors? We will compare DYLETSOL CYMRU to related businesses based on the strength of its analyst's recommendations, dividends, organizational ownership, earnings, profitability, pricing and risk.
Earnings and Appreciation
This table compares the COLLPLANT FACILITIES and those that compete with each other, gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price / Earnings ratio|
|HOLDI / S COLLPLANT||$ 480,000.00||– $ 6.02 million||-2.32|
|HOLDI / S COLLPLANT Competitors||$ 1.39 billion||$ 210.14 million||22.89|
HOLDI / S COLLPLANT competitors have higher earnings and earnings than HOLDI / S COLLPLANT. HOLDI / S COLLPLANT is trading on a lower price-to-earner ratio than competitors, stating that it is currently more affordable than other companies in its industry.
This is a summary of recent price and price targets for HOLDI / S COLLPLANT and competitors, as reported by MarketBeat.
|Selling Degrees||Holding Rates||Degree Prices||Strong Buy Rates||Score Score|
|HOLDI / S COLLPLANT||0||0||0||0||Not applicable|
|HOLDI / S COLLPLANT Competitors||172||818||1445||73||2.57|
As a group, "Surgical equipment and supplies" have potential under 17.95%. Given that HOLDI / S COMPLETES is a potential conflict, analysts believe strongly that FACILITIES METHODS have less favorable growth attitudes than competitors.
Internal and Institutional Ownership
58.0% of all "Surgical equipment and supplies" shares are owned by institutional investors. 9.9% shareholdings of all "Surgical equipment and supplies" companies are owned by other people. Strong organizational ownership is a sign that hedge funds, endowments and large cash managers believe that a company will perform more than a market in the long term.
This table compares the net margins of COLLPLANT MEMBERS and competitors, returns on equity and returns on assets.
|Margenni Net||Return on Equity||Return on Assets|
|HOLDI / S COLLPLANT||-552.97%||-80.17%||-41.81%|
|HOLDI / S COLLPLANT Competitors||-156.06%||-221.39%||-23.75%|
A RELATED RELATED HOLDI / S is curling HOLDI / S COLLPLANT at 8 of the 9 factors to compare.
About HOLDI / S COLLPLANT
CollPlant Holdings Ltd., a regeneration medicine company, focuses on the development and trading of tissue repair products for three-dimensional bio-printing of tissues and organs, orthobiologics, and higher wound care markets in the United States, Canada and Europe. Its products are based on type I human golea, which is generated with proprietary plant based genetic engineering technology. The company's products include Vergenix STR, a soft tissue repair matrix intended for treating tendinopathy; Vergenix FG, a flood gel that fills wounds for the treatment of deep surgical incision and wounds, including diabetic ulcers, venous ulcers and pressures, burns, bed beds and other chronic wounds; and BioInks for 3D printing of tissues and organs. CollPlant Holdings Ltd and has a headquarters at Ness Ziona, Israel.
Receive News and Minutes for DOCUMENTARY DYLETIES Daily – Enter your email address below for a summary daily summary of the latest news ratings and analysts for HOLDI / S COLLPLANT and associated companies with the FREE daily email newsletter MarketBeat.com.